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Transforming Growth Factor-beta (TGF-β) との拮抗作用による
Hepatocyte Growth Factor (HGF) の抗腎線維化作用の検討
井　上　　勉
Hepatocyte Growth Factor (HGF) Prevent Progression of Renal Interstitial Fibrosis via Its Counteraction 
Against Transforming Growth Factor-beta (TGF-β) in 5/6 Nephrectomized Mice
TSUTOMU INOUE (Department of Nephrology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 
350-0495, Japan)
5/6 nephrectomy (Nx) causes a progressive form of chronic renal injury in rats. However, 5/6 Nx seldom induces 
severe renal injury in mice, and the reason remains unclear. Transforming growth factor-β(TGF-β) is known as 
a key cytokine involving in organ fibrosis. Connective tissue growth factor (CTGF) is an important downstream 
mediator of profibrotic activities of TGF-β. Hepatocyte growth factor (HGF) originally identified as a potent mitogen 
for hepatocyte has been shown to promote tubule repair following acute renal injury. In renal fibrosis, HGF has been 
assumed to block profibrotic effects of TGF-β, attenuating renal fibrosis. However, such a counteraction between 
HGF and TGF-β remains to be determined in detail. Then we investigated the mechanism of the anti-fibrotic effects 
of HGF on renal fibrosis using the 5/6 Nx model in the wild and TGF-β1 transgenic mice and the co-culture system.
In wild type mice, ribonuclease protection assay (RPA) revealed that HGF and TGF-β1 mRNA levels in the remnant 
kidneys simultaneously increased at 8 hours after the nephrectomy, then decreased, and increased again at week 
4 to 12. CTGF andα1(I)procollagen mRNA levels also increased at 8 hours, then decreased, but didn’t increased 
again. In the remnant kidneys of 5/6 Nx mice, endogenous HGF seemed to prevent renal fibrogenesis promoted 
by TGF-β1. In co-culture system, RPA revealed that TGF-β1 alone could significantly enhance the expression of
α1(I)procollagen mRNA in renal tubulointerstitial fibroblasts (TFB) in the co-culture with renal proximal tubular 
epithelial cells (PTEC). In contrast, TGF-β1 with HGF did not enhance the expression ofα1(I)procollagen mRNA 
in TFB in the co-culture. This enhancement was partially because of additional production of CTGF by PTEC 
stimulated by TGF-β1 in the co-culture. In 5/6 Nx TGF-β1 transgenic mice, excess TGF-β1 caused significant 
interstitial fibrosis compared to the 5/6 Nx wild mice at week 12. The supplement of recombinant HGF was 
demonstrated to suppress CTGF expression thereby preventing renal fibrosis.
In conclusion, profibrotic effects of TGF-β1 on TFB was enhanced by the co-existence of PTEC, and HGF can 
modulate such interaction, resulting in the antifibrotic effects. This anti-fibrotic effect of HGF against TGF-β1 was 
demonstrated to be mediated by suppressing CTGF mRNA expression in the tubular epithelial cells induced by 
TGF-β1.
Keywords: transforming growth factor-β(TGF-β), connective tissue growth factor (CTGF), hepatocyto growth 
factor (HGF), nephrectomy, renal fibrosis
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動物：TGF-β transgenic mouse（TGF-β TG mouse，




negativeの個体をwild type mouse（WT mouse）として
用いた．
動物modelの作成：実験群はWT mouse 5/6腎摘













の変化を検討するためTGF-β TG mouse 5/6 腎摘dHGF
投与群 （TGNx＋dHGF）（n＝35）およびcontrol群とし
てTGF-β TG mouse 5/6 腎摘Phosphate-Buffer Salines
（PBS）投与群（TGNx＋PBS）（n＝58）用いた（Fig. 1B）．

























O.C.T. Compound（Sakura Finetechnical Co., Ltd., 
Tokyo, Japan）に包埋，急速凍結した．Cr yostatで












御供与頂き，共にDulbecco’s Modified Eagle Medium
（D-MEM），10％ fetal calf serum（FCS），100 U/ml 
penicillin，100μg/ml streptomycinで継代維持し，供与
後 5～7継代の細胞を実験に用いた．各処置前の培養細
胞のrestingには無血清培地（K-1 medium: D-MEM/F 
12，5μg/ml transferrin，5μg/ml insulin，5×10−8 M 
hydrocortisone）を用いた 20)．




pore sizeのculture insert （FALCON CELL CULTURE 
INSERTS, BECTON DICKINSON, NJ. USA）にPTEC
細胞を 30000個/㎠の濃度で播種し，24時間後に上
記と同様に播種したTFB細胞の 6 well plateに重層
し，同時に無血清培地に交換の後，72時間restingし
たものをPTEC/TFB共培養系として実験に供した
（Fig. 2）．Recombinant Human TGF-β（rhTGF-β）
（R&D Systems, Inc. MN. USA）10 ng/ml，rhTGF-β10 










は TRIzol（GIBCO BRL, Grand Island, NY, USA）を
用いて total RNA を抽出し試料とした．cRNA 
probe合成に用いた templateを以下に示す．Glyc
eraldehyde-3-phosphate dehydrogenase（GAPDH）
（115bp, 673 to 787 corresponding to rat GAPDH）21)
および TGF-β1（255 bp, 500 to 754 corresponding 
to rat TGF-β1［gb:RTGFB1］）は新潟大学腎研究施
設構造病理学分野山本格教授から御供与頂いた．
HGF（252 bp, 963 to 1214 corresponding to rat HGF
［gb:E03330］），CTGF（202 bp, 731 to 932 corresponding 
to mouse CTGF［gb:MUSFISP12B］），およびα1（Ⅰ）
procollagen （285 bp, 625 to 909 corresponding to mouse 
α 1（Ⅰ）procollagen［gb:MUSC1AIB］）は当教室で
reverse transcribed-polymerase chain reaction（RT-PCR）
Fig. 1. Experimental schedule of 5/6 nephrectomy and dHGF administration. The vertical arrows 
indicate time points of sacrifice.
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にて取得した．32P-UTP label した cRNA probe と
10μ gの total RNAを 45℃，16時間 hybridizationの
後，ribonuclease A （1.2μ g/ml）および ribonuclease T1 
（120 U/ml）で 30℃，60分処理した．Proteinase K （0.45 
μ g/ml） 37℃，60分処理にて ribonucleaseを不活化
し，ethanol沈殿にて精製後，6％の acrylamide変性 gel
を用いて protected-bandを分離した．−80℃で 3時間か
ら 5日間 autoradiographyの後，filmを透過型 scanner 
（GT-9600, EPSON, Nagano, Japan）で取り込み，各
protected-band を NIH image（1.62, NIH Division of 
Computer Research and Technology, Bethesda, MD, 
USA）を用いて定量した．各 mRNA量は GAPDHと
の比で標準化し，in vivoの実験では WT mouseの





処 理 はStatViewSE （Macintosh Version 1.03, Abacus 




































Fig. 2. Experimental design of cell culture. In this study, we used two culture systems; co-culture 







かった（1.32±0.06 vs 2.14±0.07, p＜0.05）．rhTGF-









0.13 vs 1.57±0. 07 n.s.）（Fig. 6）．
PTECのCTGF mRNA発現量はrhTGF-β（10 ng/ml）
刺激でcontrolと比して有意に増加を認め（1.00 
vs 2.23± 0.20 p＜ 0.05），rhTGF-β（10 ng/ml）＋
rhHGF （100 ng/ml）でrhTGF-β単独刺激時と比して
有意な減少を認めた（2.23±0.20 vs 1.55±0.20 p＜
0.05）．また，CTGF中和抗体添加でもrhTGF-βによ
Fig. 3. Light microscopic fi nding of remnant kidney tissues from WTNx mice (A and B) and TGNx mice (C and D). The 
interstitium was nearly normal in both groups at day 0 (A and C). There were no tubulointerstitial alterations in WTNx group 
at 12 weeks after nephrectomy (B). In contrast, kidney tissues of TGNx group at 12 weeks showed interstitial expansion and 
increased extra cellular matrix accumulation (D). (H.E. staining, Mo.: 20×)
Fig. 4. Changes in mRNA expression of fi brosis-related 
















Fig. 5. Quantifi cation of mRNA expression of fi brosis-related molecules in the remnant kidney of WTNx group. The peak of all 
mRNA expression occured at 8 hours after the total left nephrectomy. The expression levels gradually decreased to the basal 
levels by 2 weeks (A-D). HGF and TGF-β expression levels re-increased and reached to the second peak at 8weeks after the 
nephrectomy (A and B), in contrast, CTGF andα1(I)procollagen expression levels remained low until 12 weeks (C and D).
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Fig. 6. Quantifi cation ofα1(I)procollagen mRNA expression 
in TFB. Expression ofα1(I)procollagen mRNA increased 
in TFB in the co-culture with PTEC more than the one 
in the monolayer culture of TFB. The increase in theα
1(I)procollagen mRNA expression was inhibited by HGF or 
anti-CTGF antibody to the control level.
Fig. 7.  Quantifi cation of CTGF mRNA expression in 
PTEC. TGF-β1 stimulated PTEC to produce CTGF, and this 
production was partially, but signifi cantly blocked by HGF.
Fig. 8. Changes inα1(I)procollagen mRNA expression in the remnant kidneys of WTNx group and TGNx group. (The data 
of WTNx group are the same as shown in fi g. 5D.) The expression ofα1(I)procollagen mRNA signifi cantly increased in the 















































Fig. 9. Quantifi cation of CTGF mRNA in the remnant 
kidneys of TGNx＋PBS group and TGNx＋dHGF group. 
CTGF mRNA expression was signifi cantly reduced in the 
remnant kidney of TGNx＋dHGF at 6 and 8 weeks after the 
nephrectomy.
Fig. 10. Quantifi cation ofα1(I)procollagen mRNAs in the 
remnant kidneys of TGNx＋PBS group and TGNx＋dHGF 
group. Reduction in CTGF mRNA expression in the remnant 
kidney of TGNx＋dHGF group at 6 and 8 weeks after the 





























Fig. 11. Histology of the remnant kidney tissues of TGNx＋PBS group and TGNx＋dHGF group. The remnant kidney of both 
groups at 2 weeks after the nephrectomy showed slightly widened interstitium (A and B). The remnant kidney tissue of TGNx
＋PBS group at week 6 (C and D) shows tubular atrophy, interstitial expansion and increased matrix accumulation, however 
in the remnant kidney of TGNx＋dHGF group such alterations were signifi cantly attenuated (E and F). (Left column; H.E. 





























Fig. 14. CTGF protein expressed in the remnant kidney of 
TGNx＋PBS group at 8 weeks after the nephrectomy. CTGF 
protein was localized in the tubular epithelial cells as well as 
interstitial cells (A). No signals were observed in the negative 
control (B).
Fig. 12. Quantitative analysis of interstitial fi brosis by 
light microscopy. Fibrosis area in blue in the MT stained 
section was measured quantitatively by computer-assisted 
image analyzer. It revealed that the supplement of dHGF 
signifi cantly prevented interstitial fi brosis. 
Fig. 13. Life Survival of the nephrectomized mice in TGNx
＋PBS group and TGNx＋dHGF group. Life-table analyses 
are presented as Kaplan-Meyer plot. The survival rate was 
signifi cantly improved in the nephrectomized mice treated 
with dHGF in TGNx＋dHGF group.
23TGF-βとの拮抗作用による HGFの抗腎線維化作用の検討
いた検討で，TGF-β，HGFの再上昇が見られる腎








尿細管障害，間質への type I collagen沈着を抑制した






生亢進を抑制する 31)，あるいはalpha smooth muscle 
actin （α-SMA）陽性尿細管上皮に作用しmatrix 
metalloproteinase-9（MMP-9）産生を増加，tissue 
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